CML/CD36 accelerates atherosclerotic progression via inhibiting foam cell migration

Area of Science:

• Cardiovascular Research
• Diabetes Complications
• Atherosclerosis Pathogenesis

Background:

• Atherosclerosis, a major complication of type 2 diabetes mellitus, is characterized by macrophage-derived foam cell accumulation in plaques.
• Reduced macrophage migration from lesions contributes to foam cell retention and atherosclerotic progression.
• Nε-carboxymethyl-Lysine (CML), an advanced glycation end product, is implicated in diabetes complications.

Purpose of the Study:

• To elucidate the mechanism by which CML/CD36 accelerates atherosclerotic progression by inhibiting foam cell migration.
• To investigate the in vivo and in vitro effects of CML/CD36 on macrophage foam cell behavior.

Main Methods:

• In vivo studies using diabetic apoE-/- mice to assess atherosclerotic progression and foam cell migration.
• In vitro studies using RAW264.7-derived foam cells to analyze migration inhibition mechanisms.
• Analysis of pathways including NOX-derived ROS, FAK phosphorylation, Arp2/3 complex activation, and F-actin polymerization.

Main Results:

• CML/CD36 promoted foam cell accumulation in the aorta of diabetic mice.
• CML/CD36 inhibited the migration of aortic foam cells to the para-aortic lymph node in vivo.
• In vitro, CML/CD36 inhibited RAW264.7 foam cell migration via ROS, FAK phosphorylation, Arp2/3 activation, and F-actin polymerization.

Conclusions:

• CML/CD36 significantly inhibits foam cell migration from atherosclerotic plaques to lymph nodes, thereby accelerating atherosclerosis.
• The underlying mechanism involves CML/CD36-mediated effects on free cholesterol, ROS generation, FAK phosphorylation, Arp2/3 complex, and F-actin polymerization.
• Targeting the CML/CD36 pathway may offer a therapeutic strategy for diabetic atherosclerosis.